The research, recently published in the journal Alzheimer’s & Dementia: Behavior and Socioeconomics of Aging, draws from simulated patient cohorts integrating data from prior studies. Approximately 1,000 virtual patients were modeled, split evenly between those diagnosed with mild Alzheimer’s disease and those with mild cognitive impairment (MCI), a precursor to Alzheimer’s. The simulation assessed various care strategies, including usual care, collaborative care programs, administration of lecanemab, and a combination of the two. The key outcome metric was quality-adjusted life years (QALYs), a composite measure reflecting both the quantity and quality of life, which is critical when assessing interventions in chronic neurodegenerative diseases.

Results were striking. Patients enrolled in collaborative care programs experienced an average gain of 0.26 QALYs compared to those receiving standard care. Notably, the addition of lecanemab to such programs yielded further incremental improvement—increasing QALYs by another 0.16 years. This suggests a synergistic effect when combining expert-led supportive care with emerging pharmacotherapies. Importantly, the collaborative care framework not only improved health outcomes but also reduced overall healthcare costs by approximately $48,000 per patient, driven primarily by a decline in hospital visits and delayed nursing home placement.

UCSF’s collaborative care paradigm is exemplified by its Care Ecosystem program, which directly supports both dementia patients and their caregivers. Central to this model are paid patient navigators who provide continuous, personalized assistance, coordinating medical care and facilitating access to community resources. Such navigators act as vital liaisons between clinical teams and families, thereby alleviating caregiver burden—a significant factor influencing patient outcomes and healthcare utilization. Over 50 health systems nationwide have since adopted variants of this model, underscoring its scalability and adaptability.

One intriguing aspect uncovered by the UCSF study is the inclusive applicability of collaborative care programs across a wider dementia patient population compared to lecanemab. The drug is licensed specifically for individuals with mild Alzheimer’s or MCI, restricting its use to a narrow clinical subset. In contrast, collaborative care may be adapted for people with advanced dementia stages and those suffering from non-Alzheimer’s dementias, which account for up to 40% of dementia cases. This broader applicability positions collaborative care as a critical pillar in holistic dementia management strategies.

The study’s economic analysis highlights critical disparities in access to advanced pharmacotherapy. Lecanemab, with an estimated additional cost of $38,400 per patient, may remain prohibitively expensive for low-income individuals and those residing in rural areas distant from specialized memory clinics. Such systemic barriers risk widening health inequities unless offset by supportive measures like collaborative care programs, which demonstrate substantial cost savings while providing tangible quality-of-life benefits.

From a clinical neuroscience perspective, collaborative care enhances patient outcomes through multidimensional interventions—ranging from medication management to psychosocial support and connection with social services. The role of navigators transcends mere case management; they empower caregivers with education, emotional support, and strategies for managing complex behavioral symptoms that often accompany dementia. By reducing caregiver stress, these programs indirectly improve patient prognosis by fostering more stable home environments and reducing premature institutionalization.

Future therapeutic advances will invariably introduce new drugs and possibly disease-modifying agents to the armamentarium against Alzheimer’s. However, UCSF Professor Katherine L. Possin, PhD, emphasizes that pharmacotherapy alone cannot meet the comprehensive needs of dementia patients. Instead, care strategies must evolve toward integrated models that marry novel pharmaceuticals with collaborative care frameworks. This synthesis promises to optimize outcomes by addressing the biological, psychological, and social dimensions of dementia—a particularly challenging condition characterized by progressive cognitive decline and multifactorial morbidity.

Furthermore, the findings demonstrate that collaborative care extends the time patients spend living at home before requiring nursing facility placement—by an average of four months. This prolongation is not merely a metric of delayed institutionalization but represents retained autonomy, social engagement, and quality of life. From a health policy and system design perspective, such delays translate to significant economic savings and better resource allocation in an aging society increasingly burdened by dementia-related care demands.

The study’s co-authors, including Dr. James G. Kahn of UCSF, call for a fundamental rethinking of dementia care delivery. The integration of patient navigators into clinical care pathways creates a new paradigm in patient-centered care, leveraging real-time adaptability and personalized support. This approach reduces hospital readmissions and emergency visits, illustrating that improved health outcomes do not necessarily require costly pharmaceuticals alone but also depend on the structural redesign of healthcare delivery.

In summary, UCSF’s research offers a powerful argument for expanding collaborative care programs nationwide, advocating that these models complement emerging pharmacotherapies like lecanemab. As more innovative Alzheimer’s treatments receive approval, the healthcare system’s ability to effectively implement integrated care will determine their ultimate impact. Collaborative care programs ensure that advances in drug development translate into meaningful, accessible, and equitable benefits for the diverse population affected by dementia.

The implications extend beyond individual patient care to encompass health economics, caregiver well-being, and sociomedical integration. Collaborative care programs redefine dementia management through a comprehensive, multidisciplinary approach that addresses the complexity of this neurodegenerative disorder. As the dementia pandemic accelerates globally, UCSF’s findings provide a roadmap toward more effective, humane, and sustainable care strategies that balance medical innovation with compassionate support.

Subject of Research: Collaborative care programs versus pharmacotherapy with lecanemab in dementia management

Article Title: For Dementia Patients, Easy Access to Experts May Help the Most

News Publication Date: February 5

Web References:

• UCSF Care Ecosystem: https://cisionone-email.ucsf.edu/c/eJw0zruO5CAUBNCvgQwLLtc8AoLZwF-w-YjHRY3ajxmD19q_X3VrJyrplEqqEmalTeEUlDXeOAd25o_gk5Uzoq5aKZkyogWFWZmYLVG0nrdgvE2YM5qCBJ8qVwnSeKWcYyh7K_Rs32KLbaWzC4c-1-RNdgLcc0vTq-BreIzx1Zn-YLAwWO77nq7c60TlYrDsdHcGC0jQDBbpGSwIRoFisAxaKceTRL5GF_noo4t0vOP7imsbf8XaKolCG-2jRfEVR6N9dL5RaVGctFLsJFoJb_j8D0x_gPJaW36GX-dxPGn6_TjOfRw7Q_lzjvdxEm2vtQVvAWUWPnslsFYvnE9aVIhok5lnLIn_CfAvAAD__z-lb7s
• Alzheimer’s & Dementia: Behavior and Socioeconomics of Aging: https://cisionone-email.ucsf.edu/c/eJwsy71y6yAQQOGngQ4NLCtgCwrfQk9wew8_S8zYshKQ8_wZZ9J-Z06Nq7GuSo7GO3IhgF_lLZqWsWCyhM1CTQU5U9NQWKO1qVbZoyOfsRR0FRmupjQN2pExIQjUs1e-9y-1p_7gMVVAKi2TK0FBuO95eQf5iLfz_JzCXgRsArZ69OUYHwI2oxejNQjY8kx28VqvKHeuPanBD06TVa_xF65_IOwFDFnr5Yj_xnHcefl_O8bzPJ4C9avMtnB9yXkO5v19eyAPqIuiQkZha6QCZasaJPTZrSvWLL8j_AQAAP__WGdWbA

References: UCSF study led by Kelly J. Atkins, DPsych, and Katherine L. Possin, PhD, with funding from NIH/National Institute on Aging and the Alzheimer’s Association.

Keywords: Dementia, Alzheimer’s disease, mild cognitive impairment, collaborative care, patient navigators, lecanemab, health care costs, caregiver burden, quality-adjusted life years, nursing home delay, health care delivery, personalized medicine.

BOSTON – April 1, 2025 – Most people donning virtual reality (VR) goggles are seeking the thrill of being immersed in a fictitious video game world. But some are donning them for an entirely different experience: to help researchers identify those most at risk of developing Alzheimer’s disease. 

“We know that early detection of Alzheimer’s disease and other dementias can have a significant impact on the quality of life of the affected persons, through deployment of lifestyle changes and medications that can slow down disease progression,” says Manu Madhav, a neuroscientist at the University of British Columbia. “However, diagnosis has to be done through collecting biomarkers that are expensive and invasive and thus require sufficient indication of functional impairment.” This leaves opportunity for non-invasive behavioral and cognitive assessments that can give clinicians another tool for early diagnosis – and that’s where VR comes into play.

As will be presented today at the annual conference of the Cognitive Neuroscience Society (CNS) in Boston, Mass., cognitive neuroscientists are increasingly turning to VR technology to develop innovative ways to assess cognitive decline. Their work builds off past research on the role of spatial memory in Alzheimer’s disease but takes the traditional 2-D tasks and transforms them into high-tech, 3-D immersive experiences. New data is finding significant age-related and disease-related differences in how individuals can navigate and locate objects within a VR space, in some cases linking cognitive impairments to build up of Alzheimer’s proteins in the brain.

Exploring spatial memory and navigation

About 1 in 13 people between the ages of 65 and 84 will develop Alzheimer’s disease, according to the National Institute on Aging, and that number is projected to rise as life expectancy increases. But for cognitive neuroscientist Tammy Tran, studying memory and Alzheimer’s disease is about more than statistics. Like so many people, she has had loved ones develop memory disorders, and after reading Oliver Sacks’ The Man Who Mistook his Wife for a Hat as a teenager, her fascination with memory really took off.

“Episodic memory is so fascinating to me because your experiences and memories shape and define you as an individual,” says Tran of Stanford University, who is chairing a symposium on VR and memory at the CNS meeting. “What happens when you forget and lose those experiences?” 

Tran will be presenting new, pre-press work, led by Hadi Hosseini (Stanford), that shows how VR-based memory assessments can be used in combination with biofluid biomarkers of Alzheimer’s to predict who might be at risk of developing the disease. Working with young adults, clinically unimpaired older adults, and patients with mild cognitive impairment (often a precursor to Alzheimer’s), her team asked participants to remember the location of different objects, such as a TV remote or glasses, within a VR living room. They were also asked to recreate the living room environment in a later task. 

“We found decreased object location memory, as well as decreased precision for the object location memory, between young adults and older adults and unimpaired participants and those with mild cognitive impairment,” she says.

To better contextualize these assessments, they worked with neurologists to collect Alzheimer’s disease biofluid biomarkers, specifically plasma Aβ42/Aβ40 and pTau217 from the older adult participants. “We found that pTau217 predicted both object location memory and location precision performance across our sample,” Tran says. “These findings indicate that across both clinically unimpaired older adults and patients with mild cognitive impairment, presence of Alzheimer’s proteins significantly impacts memory performance.” 

This work is consistent with an emerging research that indicates that the presence of Alzheimer’s proteins impact memory function in subtle but detectable ways before the onset of clinical symptoms. Linking these Alzheimer’s disease biomarkers to cognitive function using immersive VR is something that would have been unimaginable even 5 years ago, Tran says. That’s because of research made possible by NIH funding, as well as the work of advocacy of organizations like the Alzheimer’s Association, that has transformed diagnosis of the disease – moving from post-mortem biomarker analysis, to imaging, and then cerebrospinal fluid, biomarkers, to collecting proteins from blood plasma.

The work is also exciting in how it has transformed an entertainment technology for clinical uses. “I’ve been working in the Alzheimer’s field for about 10 years, and I have never seen such excitement from participants when they’re doing an experiment,” Tran says. “For many people, this is their first experience with immersive virtual reality but since the movement is meant to mimic real-life, it is remarkably easy for them to pick up an item, walk around the room, and interact with the virtual world.”

The innovative use of VR technology in cognitive neuroscience is what attracted Manu Madhav to the research. An engineer and roboticist by training, he was fascinated by the parallels between the way robots process and integrate sensory information, and the way human brains evolved to do the same. After working on spatial navigation in rodents, he had the opportunity to collaborate with a center for Alzheimer’s disease to develop VR methods for measuring spatial navigation impairments in Alzheimer’s patients. 

“Engineering VR to be comfortable and intuitive for older participants has been the greatest challenge,” he says. “We managed to find small but significant improvements that nevertheless have made it possible to place older participants in an immersive VR environment for over an hour with minimal concerns of nausea or disorientation.” These VR systems integrate sensors for head and eye tracking, as well as controllers that can allow for rich and expressive input. 

Madhav’s team’s work is now in the early phase, working with healthy older adults and young adults but has already shown promise. They asked participants to navigate a series of corridors in a VR space while keeping track of their starting location and the locations of periodically hidden landmarks. 

“We have found that healthy younger and older adults differ in their navigational abilities, setting the stage for our recruitment of participants with early Alzheimer’s disease scheduled to begin this year,” he explains. “We expect that the presence of different complexity levels across trials will amplify differences between younger and older participants, and between older participants and those diagnosed with early Alzheimer’s disease.”

Madhav sees VR as an exciting tool not only for understanding and diagnosing Alzheimer’s disease but also for exploring other cognitive questions and disorders. “The recent, unprecedented increase in accessibility to VR systems should allow for cognitive neuroscience labs with comparatively less expertise to jump into the space and leverage VR to answer complex cognitive questions that require immersion and multimodal feedback.”

–

The symposium “Harnessing virtual reality to study memory and spatial navigation across the lifespan” is taking place at 1:30pmEDT on Tuesday. April 1, as part of the CNS 2025 annual meeting from March 29-April 1, in Boston.

CNS is committed to the development of mind and brain research aimed at investigating the psychological, computational, and neuroscientific bases of cognition. Since its founding in 1994, the Society has been dedicated to bringing its 2,000 members worldwide the latest research to facilitate public, professional, and scientific discourse.

Meeting

32nd Meeting of the Cognitive Neuroscience Society